



August 1, 2024

## **Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets**

SAN FRANCISCO, Aug. 1, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2024 on Thursday, August 8, 2024, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: <http://ir.nektar.com/>. The web broadcast of the conference call will be available for replay through September 8, 2024.

To access the conference call, please pre-register at [Nektar Earnings Call Registration](#). All registrants will receive dial-in information and a PIN allowing them to access the live call.

### **About Nektar Therapeutics**

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Our pipeline also includes a preclinical candidate NKTR-0165, which is a bivalent tumor necrosis factor receptor type II agonist antibody. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit [www.nektar.com](http://www.nektar.com) and follow us on LinkedIn.

### **Contacts:**

#### **For Investors:**

Vivian Wu of Nektar Therapeutics  
(628) 895-0661

#### **For Media:**

David Rosen of Argot Partners  
(212) 600-1902  
[david.rosen@argotpartners.com](mailto:david.rosen@argotpartners.com)

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-second-quarter-2024-on-thursday-august-8-2024-after-close-of-us-based-financial-markets-302212901.html>

SOURCE Nektar Therapeutics